Recent advances in anti-infective drug discovery最新文献

{"title":"Eco-friendly Biosynthesis of Ag-NPs by Streptomyces griseus With Anti- Candida albicans and Antitumor Activity.","authors":"Inas M Abou El-Enain,&nbsp;Nermine N Abed,&nbsp;Eman E Helal,&nbsp;Eman S Abdelkhalek,&nbsp;Waleed Suleiman,&nbsp;Nesreen A Safwat,&nbsp;Mohammed Yosri","doi":"10.2174/2772434418666230427165013","DOIUrl":"https://doi.org/10.2174/2772434418666230427165013","url":null,"abstract":"<p><strong>Background: </strong>The most significant sexually transmissible fungal disease, semen candidiasis, is caused by Candida albicans and impacts male reproductive potential. Actinomycetes are a group of microorganisms that could be isolated from various habitats and used for the biosynthesis of various nanoparticles with biomedical applications.</p><p><strong>Objective: </strong>Testing antifungal activity of biosynthesized Ag nanoparticles versus isolated C. albicans from semen as well as its anticancer activity versus the Caco-2 cell line.</p><p><strong>Methods: </strong>Screening 17 isolated actinomycetes for the biosynthesis of Ag nanoparticle biosynthesis. Characterization of biosynthesized nanoparticles, testing its anti-Candida albicans, and antitumor activity.</p><p><strong>Results: </strong>Streptomyces griseus was the isolate that identified silver nanoparticles using UV, FTIR, XRD and TEM. Biosynthesized nanoparticles have promising anti-Candida albicans with MIC (125 ± 0.8) µg/ml and accelerate apoptotic rate versus Caco-2 cells (IC50 = 7.30 ± 0.54 µg/ml) with minimal toxicity (CC50 = 142.74 ± 4.71 µg/ml) versus Vero cells.</p><p><strong>Conclusion: </strong>Certain actinomycetes could be used for the biosynthesis of nanoparticles with successive antifungal and anticancer activity to be verified by in vivo studies.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9399918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological Importance and Therapeutic Potential of Calycopterin From Dracocephalum kotschyi: An Overview of Current Scientific Research Work.","authors":"Dinesh Kumar Patel,&nbsp;Kanika Patel","doi":"10.2174/2772434418666230406092739","DOIUrl":"https://doi.org/10.2174/2772434418666230406092739","url":null,"abstract":"<p><strong>Background: </strong>Dracocephalum kotschyi Boiss is an important medicinal plant of Asia, Europe and Iran. The therapeutic potential of Dracocephalum kotschyi has been mentioned in traditional as well as in modern medicine, mainly due to its therapeutic effectiveness against different types of human disorders and associated secondary complications. Calycopterin is a flavonoid class phytochemical commonly called 5,4-dihydroxy-3,6,7,8- tetramethoxyflavone, which has been isolated from Dracocephalum kotschyi. It is widely used for the treatment of human disorders and associated secondary complications.</p><p><strong>Methods: </strong>Medicinal importance and therapeutic potential of calycopterin was investigated in the present work through scientific data analysis of different research works. Scientific data on calycopterin published in different research articles were collected from PubMed, Google, Google Scholar, Science Direct, SpringerLink, and Scopus and analyzed in the present work. Further, scientific data was collected from books and book chapters. Analytical data on calycopterin was also collected and analyzed in the present work.</p><p><strong>Results: </strong>Scientific data analysis of different research work revealed the biological importance and therapeutic potential of calycopterin. Calycopterin showed therapeutic effectiveness against different types of cancerous disorders, including human prostate cancer, breast cancer, cervical cancer, lymphocyte proliferation and hepatoblastoma cancer. Moreover, the biological effectiveness of calycopterin on neuroprotection and Pseudomonas aeruginosa has also been discussed in the present work with their pharmacokinetic parameters. Nevertheless, more scientific investigations must be conducted to explore the healthbeneficial aspects of calycopterin in medicine.</p><p><strong>Conclusion: </strong>Present work signified the biological importance and therapeutic potential of calycopterin for the treatment of human disorders and complications, including different types of cancerous disorders.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9267232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Prospects in Rheumatoid Arthritis: Pathophysiology, Genetics, and Treatments.","authors":"Shoaib Khan,&nbsp;Krishna Mohan,&nbsp;Sazina Muzammil,&nbsp;Md Aftab Alam,&nbsp;Khalid Umer Khayyam","doi":"10.2174/2772434418666230406083149","DOIUrl":"https://doi.org/10.2174/2772434418666230406083149","url":null,"abstract":"<p><strong>Background: </strong>An autoimmune inflammatory disease, rheumatoid arthritis (RA), predominantly affects the synovium joint lining, augmenting disability, early mortality, and socioeconomic difficulty. Therefore, current updates on pharmacological therapies are crucial for developing drugs to treat the disease at each stage.</p><p><strong>Objective: </strong>This review attempts to compile a thorough analysis of current developments in our knowledge of RA pathogenesis and disease-modifying drugs, with the aim of providing insights for next-generation RA therapeutics.</p><p><strong>Results: </strong>According to the literature, the most successful drugs for treatment techniques described so far in this include (cs) DMARDs (sub-class of DMARDs), tsDMARDS (targeted synthetic DMARDS), and bDMARDs (biological DMARDs). However, current pharmacologic therapy (consisting of biological, conventional, and creative views of small molecule anti-rheumatic drugs that treat the disease or DMARD) remains the cornerstone of rheumatoid arthritis treatment with which significant progress toward disease remission has been accomplished.</p><p><strong>Conclusion: </strong>The pathobiology of RA involves cytokine messengers such as B and T-cells, and an intricate interplay of pro-inflammatory cytokines responsible for activating and developing effector cells, in turn, accountable for local disease and systemic symptoms. Despite the fact that the cause of rheumatoid arthritis is not known, new treatments have been created as a result of better approaches towards the biology of the disease. As they target molecules directly implicated in the genesis of rheumatoid arthritis, these drugs may be more effective, targeted, and less harmful in the short and long term than standard therapies.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9267233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Covid-19 Study, Diagnostic and Therapeutic Transition.","authors":"Da Yong Lu,&nbsp;Ting Ren Lu","doi":"10.2174/2772434418666230331115936","DOIUrl":"https://doi.org/10.2174/2772434418666230331115936","url":null,"abstract":"<p><strong>Introduction: </strong>The outbreak of coronavirus (severe acute respiratory syndrome coronavirus2, COVID-19, SARS-Co-2) in Wuhan, China occurred three years ago. However, the healthcare state and legislature for Covid-19 varied greatly worldwide.</p><p><strong>Aims: </strong>After three years, the social life of most countries worldwide is gradually back to normal. Diagnosis and therapeutics worldwide are formalized now. Improvement of the knowledge about this devastating disease will shed new light on its management and spawn the development of new counter measures. Due to the differences in socioeconomic conditions and policies worldwide, the diagnostic and therapeutic transition should be established.</p><p><strong>Methods: </strong>The schedules and techniques of vaccines, drugs, or other therapeutic strategies could be formalized in the future. The origin and hidden nature of Covid-19 biology (relationship between viral strain and drug targeting) should be further investigated. Knowledge and opinion breakthroughs may significantly heighten the quality of preventive and therapeutic strategies against Covid-19.</p><p><strong>Results: </strong>To further stabilize the global situation, the issues of viral spread and induced mortality should be emphasized. Existing animal models, pathophysiological knowledge, and therapeutics for different infected patients played vital roles. The diagnostic widening, variants of COVID, and therapeutic selection worldwide totally solve the complex outcomes and promote the curability for infected patients.</p><p><strong>Discussion: </strong>Different diagnostic platforms can reach different therapeutic selections, responses, and benefits in the clinic. It will provide advanced diagnostic dimensions, therapeutic paradigms, and drug selection strategies for the purpose of the greatest benefiting and recoveries of Covid-19 patients.</p><p><strong>Conclusion: </strong>To speed up the global fight against Covid-19, biomedical knowledge, prophylactic vaccines, and therapeutic paradigms should be updated in dynamic states.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9220633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meet the Regional Editor","authors":"Michael R. Hamblin","doi":"10.2174/277243441801230117154017","DOIUrl":"https://doi.org/10.2174/277243441801230117154017","url":null,"abstract":"","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136166052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Active Compounds of Nigella sativa in COVID-19: A Narrative Review.","authors":"Usmani H, Malik S, Arya A, Mahto Pk, Kant R, Dua R, Sindhwani D, Mirza Aa, P K Panda","doi":"10.2174/2772434418666230222140805","DOIUrl":"10.2174/2772434418666230222140805","url":null,"abstract":"<p><strong>Background: </strong>SARS-CoV-2 infection that led to the COVID-19 pandemic has changed human health and the economy globally. SARS CoV-2 is a type of Coronaviruses that has caused pneumonia and its complications with many deaths over the past two years. The use of hydroxychloroquine and chloroquine, accepted as generally safe for patients with autoimmune diseases or malaria, was attempted in many trials for COVID-19 treatment. Nigella sativa (NS) (black caraway, also known as black cumin, nigella or Kalonji) is an annual flowering plant of the Ranunculaceae family, chemically composed of the main constituent natural Thymoquinone (TQ) (30%- 48%) in forms of thymohydroquinone, dithymoquinone (Nigellone) is a native to wider regions, including parts of eastern Europe, west Asia, North of Africa and east of Myanmar. In this review, we explored the Randomized Controlled Trial, Controlled Trial, and Systematic review studies that support Nigella sativa Thymoquinone-targeted SARS-CoV-2 targeting. Therefore, A literature search was performed for publications published on the electronic databases (PubMed, Embase, Scopus, CNKI, and Google Scholar) for Nigella sativa, black seeds, Kalonji, coronavirus, SARS-CoV -2 and COVID-19. This review aimed to find relevant evidence of Nigella sativa preferences as a natural feasible remedy with no side effects in COVID-19. Studies reported the benefits of NS as beneficial, another appropriate remedy for patients with COVID-19. However, all studies have shown limitations, such as limiting clinical symptom outcomes due to regulations imposed by isolation policies and lack of adequate funding. Therefore, the evidence suggests that the chemical contents of NS are a safe and possible treatment for COVID-19 patients that helps to improve COVID-19 infection in patients with no side effects.</p><p><strong>Conclusion: </strong>Nigella sativa seeds were one of the well-documented herbal products. Three reviewed randomized controlled trials reported that NS reduced covid-19 risk and could improve immune function. It was also helpful in upper respiratory infections such as asthma and bronchitis, with one RCT showing that honey and NS significantly improved symptoms, viral clearance, and mortality of COVID-19 patients. This review concludes that NS has a positive barrier effect on people at risk of acquiring a COVID-19 infection.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10758437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Convalescent Plasma the Experience and Journey from Blockbuster to Incognito: A Single Centre Experience.","authors":"Gita Negi,&nbsp;Daljit Kaur,&nbsp;Ashish Jain,&nbsp;Yatendra Kumar Mohan,&nbsp;Sushant Kumar Meinia,&nbsp;Pandeep Kaur,&nbsp;Prasan Kumar Panda,&nbsp;Deepjyoti Kalita,&nbsp;Ravi Kant","doi":"10.2174/2772434417666220622140416","DOIUrl":"https://doi.org/10.2174/2772434417666220622140416","url":null,"abstract":"<p><strong>Background: </strong>Convalescent plasma has been used to provide passive immunotherapy to patients with COVID-19 with a high level of safety. Very few efficacy studies were available, and due to COVID being a relatively new disease, its exact therapeutic role was unclear. This observational study on the impact of COVID convalescent plasma (CCP) on clinical outcomes attempts to evaluate the effectiveness of convalescent COVID-19 plasma therapy in the treatment of COVID-19 patients at the tertiary care center in the Uttarakhand state of India.</p><p><strong>Methods: </strong>CCP was collected by plasmapheresis/whole blood from willing COVIDrecovered donors who underwent pre-donation testing including ABO and RhD grouping, mandatory blood screening tests for HIV, HBV, HCV, syphilis and Malaria, Haemoglobin estimation and COVID IgG assay. Hospitalized patients with severe COVID-19 pneumonia who received these CCP units were followed up and the outcome (Recovery/death) was observed.</p><p><strong>Results: </strong>A total of 63 patients who received CCP were included in the study. Out of the total, 13 (20.7%) were females and 50 (79.3%) were males and their ages ranged from 24 to 80 years with a median age of 53 years. The period between the start of symptoms and hospitalization ranged from 1 to 14 days with an average duration of 4.7 days. Symptoms on presentation included Fever 53/63 (84.1%), Tachypnoea 60/63 (95.2%) and Cough 42/63 (66.7%). Among these patients, 22/63 (34.9%) were on non-invasive ventilation (NIV), 6/63 (9.5%) on non-rebreather mask (NRBM) and 32/63 (50.8%) were on Ventilator support. The infused convalescent plasma had a Mean IgG value of 57.3 AU with a range of (10-142 AU). A total of 37 (58.7%) patients were lost to COVID-19 infection and 26 (41.3%) were discharged from the hospital in a healthy state.</p><p><strong>Conclusion: </strong>The use of convalescent plasma in addition to standard treatment in our study on patients with severe pneumonia due to COVID-19 did not demonstrate reduced mortality of COVID-19 patients amidst numerous variables. The results showed that the use of convalescent plasma as a treatment option in the present conditions needs a serious re-evaluation. Studies on a strictly defined recipient group and transfusion of CCP units, with adequate antibody titer and/or neutralization activity, must be analyzed for future works.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"18 3","pages":"188-196"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9628417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulegone: An Emerging Oxygenated Cyclic Monoterpene Ketone Scaffold Delineating Synthesis, Chemical Reactivity, and Biological potential.","authors":"Ashwani K Dhingra,&nbsp;Bhawna Chopra","doi":"10.2174/2772434418666221018090507","DOIUrl":"https://doi.org/10.2174/2772434418666221018090507","url":null,"abstract":"<p><p>Pulegone ((R)-5-Methyl-2-(1-methylethylidine) cyclohexanone) is a pharmacologically active, natural monoterpene ketone obtained from leaves and flowering tops of the mint family (Lamiaceae). The aim is to comprise the physicochemical and biological aspects of pulegone. All significant databases were collected via electronic search using Pubmed, Scopus, Web of Science, and Science Direct and were compiled. This review presents the occurrence, chemistry, and modifications of pulegone structure and its effect on the biological system. Pulegone represents various pharmacological properties, i.e., antioxidant, antimicrobial, anti-feeding, antifungal, antiviral, and pesticide activities, and has a significant role as an abortifacient and emmenagogue. Thus, this present review concludes the knowledgeable erudition on pulegone that paves the way for further work.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"18 1","pages":"16-28"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9469980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive Multiple 2D-/3D-QSAR Modeling, Molecular Docking and Pharmacophoric Approaches for Piperazinylquinoline Derivatives as Respiratory Syncytial Virus Fusion Inhibitors.","authors":"Vipul P Purohit,&nbsp;Bapu R Thorat,&nbsp;Suraj N Mali,&nbsp;Rahul R Wagh,&nbsp;Ramesh Yamgar","doi":"10.2174/2772434418666221125090113","DOIUrl":"https://doi.org/10.2174/2772434418666221125090113","url":null,"abstract":"<p><strong>Background: </strong>The human respiratory syncytial virus (RSV) is responsible for causing upper and lower respiratory tract infections in young children. RSV Fusion (F) protein is a surface glycoprotein that facilitates virus entry into host cells. Thus, newer designing of RSV Fusion (F) protein inhibitors is required on an urgent basis.</p><p><strong>Methods: </strong>In the present study, we have developed statistically robust. Quantitative structure-activity relationship (QSAR) models for the effective designing of newer analogues of piperazinylquinoline derivatives (H1-H12).</p><p><strong>Results: </strong>Our developed models were retained with high statistical parameters (R² > 0.6 and Q² > 0.5). Our developed pharmacophore, model (AADHRR_2) (indicating that two hydrogen bond acceptors, one hydrogen bond donor, one hydrophobic group, and two aromatic rings) is crucial for retaining the activities of piperazinylquinoline derivatives against RSV. Moreover, docking analysis of 12 new analogues on RSV pre-F in complex with 5C4 Fab (PDB ID: 5W23) and post-F trimeric protein (PDB ID: 3RRR) suggested higher affinities of these molecules against studied targets with good docking scores.</p><p><strong>Conclusion: </strong>Thus, one can implement developed QSAR models, docking analogy and Pharmacophore models for identifications of potent leads for designed molecules as RSV Fusion (F) protein inhibitors.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"18 2","pages":"148-167"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9494987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Thrombolysis in COVID-19 Related ARDS.","authors":"Abhishek Goyal,&nbsp;Yogesh Niwariya,&nbsp;Neeraj Pawar,&nbsp;Alkesh Khurana,&nbsp;Poonam Chaudhary","doi":"10.2174/2772434417666221012111042","DOIUrl":"https://doi.org/10.2174/2772434417666221012111042","url":null,"abstract":"<p><strong>Introduction: </strong>COVID-19 causes significant pulmonary microthrombi in some individuals, leading to ARDS and death. Thrombolysis could be an effective approach in some patients with severe ARDS. We describe our experience with the usage of thrombolytic agents in critically ill COVID-19 patients who were in worsening respiratory failure.</p><p><strong>Methods: </strong>Retrospective chart analysis was done in patients who were thrombolysed between May 2020-Sept 2020. Analysis was done to find out factors associated with improvement in oxygenation and survival.</p><p><strong>Results: </strong>Twenty-seven patients with severe ARDS [all had respiratory rate >30, FiO2 >0.6 (on NIV/HFNC) and PiO2/FiO2 ratio <120] were thrombolysed in our ICU for COVID19 causes. C.T. Pulmonary Angiography could not be done in any of the 27 patients due to poor general condition, but 2D echo was normal in most (5 had dilated RA, RV), and none of the patients was in shock. So, there was no conventional indication of thrombolysis in these patients, yet after thrombolysis, we observed dramatic changes in oxygenation (defined by a decrease in FiO2 by ≥0.2) in twenty patients. Five patients had a major bleed. Eleven patients survived (survival rate of 40.7%) and the survival rate was high {66% (8/12)} in patients who were thrombolysed within 2 days of oxygen requirement.</p><p><strong>Conclusion: </strong>In this unprecedented pandemic with high mortality rates, efficacy of early thrombolysis needs to be further explored in randomised controlled trials.</p>","PeriodicalId":74643,"journal":{"name":"Recent advances in anti-infective drug discovery","volume":"18 3","pages":"197-204"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9578581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}